P-272 * Phase II study of Regorafenib as single agent for...

Annals of Oncology 2015 / 06 Vol. 26; Iss. suppl 4

P-272 * Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

Garcia Alfonso, P., Ortiz, M. J., Duran, G., Falco, E., Munoz, A., Garcia-Paredes, B., Salgado, M., Lopez-Ladron, A., Vieitez de Prado, J. M., Valladares, M., Salud, A., Guillen-Ponce, C., Lopez, R.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv233.269
Date:
June, 2015
File:
PDF, 35 KB
english, 2015
Conversion to is in progress
Conversion to is failed